Blood:补体激活与抗磷脂抗体综合征的血栓形成事件

2019-12-11 QQY MedSci原创

中心点:补体激活与抗磷脂抗体诱导的血栓事件相关。重度APS患者补体调节基因上的罕见胚系突变发生率高。摘要:抗磷脂抗体综合征(APS)的特征是血栓形成和复发性流产;抗磷脂抗体(包括抗β-2-糖蛋白I[抗-β2GPI])的存在被认为是APS病理的中心机制。动物研究表明补体在APS相关临床事件中具有一定作用,基于此,研究人员通过改良Ham试验(补体依赖性细胞杀伤)和细胞表面沉积C5b-9来验证补体激活与

中心点:

补体激活与抗磷脂抗体诱导的血栓事件相关。

重度APS患者补体调节基因上的罕见胚系突变发生率高。

摘要:

抗磷脂抗体综合征(APS)的特征是血栓形成和复发性流产;抗磷脂抗体(包括抗β-2-糖蛋白I[抗-β2GPI])的存在被认为是APS病理的中心机制。动物研究表明补体在APS相关临床事件中具有一定作用,基于此,研究人员通过改良Ham试验(补体依赖性细胞杀伤)和细胞表面沉积C5b-9来验证补体激活与APS的血栓形成事件相关的假设。

改良Ham(mHam)(和相应的C5b-9沉积)在CAPS的阳性率为85.7%,在APS中的阳性率为35.6%(68.5%的患者为1年内血栓),但在SLE 血清中的阳性率仅6.8%。

mHam试验阳性与三阳性(抗狼疮抗体、抗心磷脂和抗β2GPI抗体阳性)和复发性血栓形成相关。患者来源的抗β2GPI抗体也可诱导C5b-9沉积,而该过程可被抗C5单克隆抗体完全阻断,但不能被因子D抑制剂阻断,提示抗β2GPI抗体诱导补体激活主要是通过经典补体通路。

最后,与APS、SLE患者或正常对照相比,重度APS患者的补体调控基因的罕见胚系突变发生率较高(60% vs 21.8% vs 28.6% vs 23.3%),与aHUS的突变率相近。

总而言之,本研究表明抗β2GPI抗体可激活补体,促进APS血栓形成,而重度APS患者的补体调控基因上存在潜在突变,导致补体失控激活和更严重的血栓表型的“二次打击”。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1722154, encodeId=9d701e221546c, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Sat Apr 18 23:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927194, encodeId=c6d9192e1943e, content=<a href='/topic/show?id=85f5555832b' target=_blank style='color:#2F92EE;'>#抗磷脂抗体综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55583, encryptionId=85f5555832b, topicName=抗磷脂抗体综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed May 13 10:50:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431703, encodeId=249a1431e03e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592084, encodeId=d818159208476, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1722154, encodeId=9d701e221546c, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Sat Apr 18 23:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927194, encodeId=c6d9192e1943e, content=<a href='/topic/show?id=85f5555832b' target=_blank style='color:#2F92EE;'>#抗磷脂抗体综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55583, encryptionId=85f5555832b, topicName=抗磷脂抗体综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed May 13 10:50:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431703, encodeId=249a1431e03e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592084, encodeId=d818159208476, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1722154, encodeId=9d701e221546c, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Sat Apr 18 23:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927194, encodeId=c6d9192e1943e, content=<a href='/topic/show?id=85f5555832b' target=_blank style='color:#2F92EE;'>#抗磷脂抗体综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55583, encryptionId=85f5555832b, topicName=抗磷脂抗体综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed May 13 10:50:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431703, encodeId=249a1431e03e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592084, encodeId=d818159208476, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1722154, encodeId=9d701e221546c, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Sat Apr 18 23:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927194, encodeId=c6d9192e1943e, content=<a href='/topic/show?id=85f5555832b' target=_blank style='color:#2F92EE;'>#抗磷脂抗体综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55583, encryptionId=85f5555832b, topicName=抗磷脂抗体综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed May 13 10:50:00 CST 2020, time=2020-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431703, encodeId=249a1431e03e6, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592084, encodeId=d818159208476, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Fri Dec 13 10:50:00 CST 2019, time=2019-12-13, status=1, ipAttribution=)]

相关资讯

PLos One:类风湿和银屑病关节炎患者关节中的 C5a和C5aR升高

这项研究数据支持在类风湿和银屑病关节炎中,C5a-C5aR轴驱使炎性细胞浸润到滑液和滑膜中。

Lancet Neurol:依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究

研究认为,依库珠单抗治疗不能改善对抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力患者日常生活活动评分,但治疗耐受性良好且可以部分缓解患者疾病进展

Neurology:抗癫痫药导致的斑丘疹遗传突变因素研究

研究发现,补体因子H相关蛋白家族的成员CFHR4是欧洲人群抗癫痫药斑丘疹的遗传突变因素,说明补体系统替代途径调节与欧洲苯妥英引起的超敏反应之间存在联系

Neurology:自身抗体及补体途径在免疫坏死性肌病中发挥重要作用

研究发现了抗SRP和抗HMGCR抗体在免疫介导坏死性肌病中的作用,强调体液机制是免疫和肌纤维坏死的关键因素

NEJM:SOLIRIS(eculizumab)治疗神经脊髓炎视觉障碍的III期阳性数据

Alexion制药公司近日宣布,新英格兰医学杂志(NEJM)公布了成人AQP4阳性神经脊髓炎视觉障碍(NMOSD)患者首次使用SOLIRIS®(eculizumab)(补体抑制剂)治疗的III期PREVENT研究的阳性数据。

Blood:ADAMTS13缺陷和补体过度激活协同导致血栓性微血管病

血浆ADAMTS13活性重度缺陷是血栓性血小板减少性紫癜(TTP)的主要原因,而补体通过替代途径过度激活又导致了非典型溶血性尿毒症综合征(aHUS),TTP和aHUS是血栓性微血管病的两种原型。但从临床和致病机制上区别TTP和aHUS非常具有挑战性。临床报道表明补体激活可能在血浆ADAMTS13活性重度缺陷所引起的TTP发展过程中发挥作用。但目前尚无确凿的实验证据。近日,《血液》杂志上发表一篇文章